Abstract:Clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized the field of gene therapy as it has enabled precise genome editing with unprecedented accuracy and efficiency, paving the way for clinical applications to treat otherwise incurable genetic disorders. Typically, precise genome editing requires the delivery of multiple components to the target cells that, depending on the editing platform used, may include messenger RNA (mRNA), protein complexes, and DNA fragments. For clinical purposes, these have to be efficiently delivered into transplantable cells, such as primary T lymphocytes or hematopoietic stem and progenitor cells that are typically sensitive to exogenous substances. This challenge has limited the broad applicability of precise gene therapy applications to those strategies for which efficient delivery methods are available. Electroporation-based methodologies have been generally applied for gene editing applications, but procedure-associated toxicity has represented a major burden. With the advent of novel and less disruptive methodologies to deliver genetic cargo to transplantable cells, it is now possible to safely and efficiently deliver multiple components for precise genome editing, thus expanding the applicability of these strategies. In this review, we describe the different delivery systems available for genome editing components, including viral and non-viral systems, highlighting their advantages, limitations, and recent clinical applications. Recent improvements to these delivery methods to achieve cell specificity represent a critical development that may enable in vivo targeting in the future and will certainly play a pivotal role in the gene therapy field.

Gene knockout in cellular immunotherapy: Application and limitations

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy

Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

CRISPR-Cas9 Genome Editing for Cancer Immunotherapy: Opportunities and Challenges.

Molecular mechanisms, off‐target activities, and clinical potentials of genome editing systems

Applications of CRISPR technologies to the development of gene and cell therapy

Cellular Immunotherapy for Hematological Malignancy: Recent Progress and Future Perspectives.

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy

CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Genome-editing Technologies for Gene and Cell Therapy

Reprogramming natural killer cells for cancer therapy

Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics

Synthetic Cells and Molecules in Cellular Immunotherapy